Details of the Drug
General Information of Drug (ID: DM3BFX0)
Drug Name |
3-Benzyl-4-hydroxy-2H-chromen-2-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Hydroxy-3-benzylcoumarin; 15074-18-7; 3-Benzyl-4-hydroxy-2H-chromen-2-one; 3-Benzyl-4-hydroxy-chromen-2-one; 3-benzyl-4-hydroxycoumarin; 3-benzyl-4-hydroxy-2h-1-benzopyran-2-one; 3Bz-4OHBzpyran2one; 4-hydroxy-coumarin 8; CBMicro_020160; AC1L9T1B; 3-Benzyl-4-hydroxy-cumarin; Oprea1_155335; 3-benzyl-4-hydroxy-coumarin; Oprea1_579559; 3-benzyl-4 -hydroxycoumarin; SCHEMBL1648186; CHEMBL574145; BDBM2566; JMC527142 Compound 27; 3-benzyl-2-hydroxychromen-4-one; DTXSID60715769; 4-hydroxy-3-benzylchromen-2-one; MolPort-001-017-230
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 252.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||